1. Introduction {#sec1-cancers-11-00401}
===============

In head and neck squamous cell carcinoma (HNSCC), epigenomic inactivation linked to tumor suppressor genes (TSGs) is more frequent compared to somatic mutations in cancer and might drive tumorigenic initiation and progression \[[@B1-cancers-11-00401]\]. Several studies have used gene-specific and genome-wide approaches to examine epigenetic changes and methylation in HNSCC \[[@B2-cancers-11-00401],[@B3-cancers-11-00401]\]. It is widely accepted that understanding such epigenetic events is critical to elucidate the mechanisms through which environmental factors contribute to the development and progression of human cancer \[[@B4-cancers-11-00401]\]. Increasing evidence supports the existence of specific epigenetic changes related to associated risk-factor exposure, which might be exploited to discover new biomarkers that could ultimately improve the prevention, diagnosis, and treatment of cancer \[[@B5-cancers-11-00401]\].

Clinical staging and histological grading systems are convenient but imperfect predictors of recurrence. Risk factors for HNSCC development include tobacco and alcohol abuse, sexual promiscuity, and human papilloma virus (HPV) infection \[[@B6-cancers-11-00401]\]. Patients with HPV-associated oropharyngeal SCC (OPSCC) have a better prognosis than patients with HPV-negative tumors when treated with multimodal therapies \[[@B7-cancers-11-00401],[@B8-cancers-11-00401]\]. Thus, there is a need to further refine and apply concerted approaches to molecular biomarkers for HNSCC, which might help to facilitate early detection, improved monitoring, and the delivery of individualized cancer therapy.

Loss of heterozygosity (LOH) on chromosome 18q is associated with significantly decreased survival in HNSCC \[[@B9-cancers-11-00401]\]. The commonly lost region of 18q is 18q23, which is lost in 53% (D18S461) to 75% (D18S70) of cases \[[@B10-cancers-11-00401]\]. Our preliminary analyses indicated that methylation-induced galanin receptor type 1 (*GALR1*) gene silencing is a critical event in HNSCC progression and that restoring expression inhibits tumor cell growth \[[@B11-cancers-11-00401]\]. Furthermore, transcriptional inactivation of Sal-like protein 3 (*SALL3*) was found to be associated with aberrant methylation of other tumor-related genes and ten-eleven translocation (*TET*) family genes, as well as DNA methyltransferase 3 alpha (*DNMT3A*) levels, in HNSCC \[[@B12-cancers-11-00401]\]. These findings are consistent with the notion that the methylation status and inactivation of other 18q23 genes might contribute to aggressive tumor behavior in HNSCC.

To test this hypothesis, we investigated the methylation status of 18q23 genes based on two prospective cohort studies (original cohort of 243 patients and The Cancer Genome Atlas (TCGA) comprising 516 cases). We assessed such epigenetic events at diagnosis and during follow-up to assess their clinical significance and potential as prognostic biomarkers for tumor recurrence and patient survival. Furthermore, we carefully reviewed the literature with respect to the association between the methylation of 18q23 genes and survival in patients with human cancers. To our knowledge, this study is the first to implicate 18q23 gene methylation in the prognosis of HNSCC.

2. Results {#sec2-cancers-11-00401}
==========

2.1. Initial Screening: Promoter Methylation Status of 12 Genes Located on 18q23 in Matched Pairs of Head and Neck Tumors and Adjacent Normal Mucosal Tissues {#sec2dot1-cancers-11-00401}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Initially, the promoter methylation status of 12 genes was analyzed in 36 cancerous and paired noncancerous mucosae by quantitative methylation-specific PCR (Q-MSP). Promoter methylation levels were represented by normalized methylation values (NMVs), which are the ratios of methylated DNA at the target sequence in each specimen to fully methylated control DNA. We noted distinct methylation patterns as follows: (a) a higher frequency and quantity of methylated genes was noted in HNSCCs compared to that in controls with the absence of methylation in a subset of normal samples (*p* \< 0.05), including ATPase phospholipid transporting 9B (*ATP9B*), *GALR1*, potassium voltage-gated channel modifier subfamily G member 2 (*KCNG2*), par-6 family cell polarity regulator gamma (*PARD6G*), and *SALL3*; (b) a higher frequency of methylated genes was noted in HNSCC compared to that in controls but with similar quantities in both groups (*p* \< 0.10), including heat shock factor binding protein 1 like 1 (*HSBP1L1*) and nuclear factor of activated T cells 1 (*NFATC1*); (c) methylation of genes was noted in both HNSCC and controls at a similar frequency with no difference in methylation levels (*p* ≥ 0.10), including CTD phosphatase subunit 1 (*CTDP1*), PQ loop repeat containing 1 (*PQLC1*), ribosome binding factor A (*RBFA*), thioredoxin like 4A (*TXNL4A*), and zinc finger protein 516 (*ZNF516*) ([Figure 1](#cancers-11-00401-f001){ref-type="fig"}a and [Figure S1](#app1-cancers-11-00401){ref-type="app"}). Based on these results, seven genes (*ATP9B*, *GALR1*, *HSBP1L1*, *KCNG2*, *NFATC1*, *PARD6G* and *SALL3*) could distinguish HNSCC samples from normal samples, and these were selected for further testing using the expanded cohort.

2.2. Promoter Methylation Status of Seven Genes in Original and TCGA Cohorts {#sec2dot2-cancers-11-00401}
----------------------------------------------------------------------------

Q-MSP was next used to assess the promoter methylation status of seven genes located on 18q23 in 243 primary HNSCC samples. The methylation rates for these genes were as follows: *ATP9B*, 37.0%; *GALR1*, 49.4%; *HSBP1L1*, 30.5%; *KCNG2*, 59.3%; *NFATC1*, 9.1%; *PARD6G*, 40.3% and *SALL3*, 66.3% in original cohort. In the TCGA cohort, we also detected frequent methylation of *ATP9B* (33.7%), *GALR1* (95.9%), *HSBP1L1* (39.0%), *KCNG2* (68.6%), *NFATC1* (70.0%), *PARD6G* (28.9%) and *SALL3* (85.9%) in HNSCC ([Figure 1](#cancers-11-00401-f001){ref-type="fig"}b). The mean number of methylated genes per sample (original cohort and TCGA cohort) was 2.72 (range, 0--6) and 4.22 (range, 1--7), respectively. In the original cohort, at least one of these genes was methylated in most samples (231 of 243 samples, 95.1%). In the TCGA cohort, aberrant methylation of at least one of the seven genes was detected in all cases ([Figure 1](#cancers-11-00401-f001){ref-type="fig"}c). Regarding the relationships between mRNA expression and DNA methylation, Pearson correlation analysis revealed significant inverse correlations for *GALR1* and *SALL3*, positive correlations for *HSBP1L1*, and no correlations of *ATP9B*, *KCNG2*, *NFATC1* and *PARD6G* in the TCGA cohort ([Figure S2](#app1-cancers-11-00401){ref-type="app"}). From the TCGA database, the average β values for *GALR1*, *NFATC1* and *SALL3* methylation were significantly higher in the HNSCC samples than in the normal samples (*p* \< 0.001). Furthermore, the methylation of *ATP9B*, *HSBP1L1*, *KCNG2* and *PARD6G* promoters was not associated with HNSCC and normal control groups ([Figure S3](#app1-cancers-11-00401){ref-type="app"}).

2.3. Correlation between the Methylation Status of Seven Gene Promoters Located on 18q23 and Clinicopathological Parameters {#sec2dot3-cancers-11-00401}
---------------------------------------------------------------------------------------------------------------------------

The associations between the methylation status of target genes and clinicopathological features in the original cohort are summarized in [Table 1](#cancers-11-00401-t001){ref-type="table"}. A higher recurrence rate was observed for patients with methylated *GALR1* (*p* = 0.007). Methylation of *SALL3* was also associated with recurrence events (*p* = 0.033) ([Table 1](#cancers-11-00401-t001){ref-type="table"}). In the TCGA cohort, methylation of the *ATP9B* promoter was significantly correlated with tumor size (*p* = 0.023) and clinical stage (*p* = 0.006), methylation of the *GALR1* promoter was significantly correlated with lymph node status (*p* = 0.024), and methylation of the *HSBP1L1* promoter was significantly correlated with sex (*p* \< 0.001) and smoking status (*p* = 0.002) ([Table 2](#cancers-11-00401-t002){ref-type="table"}). Continuous marker methylation analyses showed no association between the methylation index (MI) of any of the seven target genes and age at disease onset, sex, alcohol consumption, smoking status, tumor size, lymph node status, clinical stage, or recurrence ([Figure S4a,b](#app1-cancers-11-00401){ref-type="app"}).

2.4. Kaplan--Meier Analysis {#sec2dot4-cancers-11-00401}
---------------------------

Based on the original cohort, Kaplan--Meier survival curves for each of the seven genes are shown in [Figure 2](#cancers-11-00401-f002){ref-type="fig"}. Disease-free survival (DFS) time did not significantly differ between patients with methylated genes and those with unmethylated genes, with two notable exceptions; this was significantly shorter when *GALR1* was methylated (*p* = 0.018; [Figure 2](#cancers-11-00401-f002){ref-type="fig"}b) and when *SALL3* was methylated (*p* = 0.013; [Figure 2](#cancers-11-00401-f002){ref-type="fig"}g). For *GALR1* and *SALL3*, the DFS rates for both unmethylated genes, either methylated genes, and both methylated genes, were 66.9%, 59.5% and 0%, respectively (*p* = 0.010; [Figure 2](#cancers-11-00401-f002){ref-type="fig"}h). Based on log-rank tests, a trend in poorer DFS for patients with the methylation phenotype, defined as ≥5 methylated genes, was observed (*p* = 0.056; [Table S1](#app1-cancers-11-00401){ref-type="app"}). To validate the prognostic implications of the methylation of the seven target genes, we examined the data for the 507 HNSCC patients in TCGA database. Methylation of any gene was not associated with an altered overall survival rate when compared to that for samples harboring low levels of methylation ([Figure S5](#app1-cancers-11-00401){ref-type="app"}).

2.5. Prognostic Value of the Methylation Status of Seven Genes Located on 18q23 {#sec2dot5-cancers-11-00401}
-------------------------------------------------------------------------------

The association between methylation and risk of recurrence was estimated via multivariate analysis using a Cox proportional hazards model adjusted for age, HPV status, smoking status, alcohol consumption, and clinical stage. In patients exhibiting *GLAR1* promoter methylation (120/243, 49.4%), the adjusted odds ratio (OR) for recurrence was 1.600 (95% confidence interval \[CI\]: 1.027--2.493, *p* = 0.038). *SALL3* methylation (161/243, 66.3%) also showed a significant association with recurrence (OR = 1.911, 95% CI: 1.155--3.162, *p* = 0.012; [Table 3](#cancers-11-00401-t003){ref-type="table"}).

3. Discussion {#sec3-cancers-11-00401}
=============

The identification of epigenetic modifications of 18q23 genes is important to elucidate the mechanisms underlying tumorigenesis and to assess recurrence risk; we studied this in 243 HNSCC patients. We found that aberrant methylation of *GALR1* and *SALL3* promoters was positively correlated with recurrence in patients with HNSCCs. To our knowledge, this study is the first to show that the epigenetic regulation of 18q23 genes can provide insights into the aggressive tumor behavior and the risk of disease recurrence in HNSCC.

It was reported that the loss of chromosome 18q develops with tumor progression and is associated with significantly decreased survival in HNSCC patients \[[@B10-cancers-11-00401],[@B13-cancers-11-00401]\]. The missing portion of 18q23 can vary from 53% (D18S461) to 75% (D18S70) and encompasses the *GALR1* and *SALL3* locus \[[@B10-cancers-11-00401]\]. Somatic gene mutations are not the only mechanism of biallelic inactivation. Loss of 18q occurs frequently in HNSCC, with the loss of 18q23 reported in 55% of HNSCCs in the TCGA database \[[@B14-cancers-11-00401]\]. In laryngeal carcinoma, loss of heterozygosity at 18q23 was found to be associated with lymph node involvement and worse prognosis \[[@B15-cancers-11-00401]\].

Interestingly, we found that aberrant methylation of *GALR1* and *SALL3* is associated with worse DFS and that this might be a critical event in HNSCC. Based on the TCGA cohort of HNSCC, *GALR1* and *SALL3* mutations occurred at low frequencies, in three (0.58%) and nine (1.75%) of 515 patients, respectively \[[@B16-cancers-11-00401]\]. Furthermore, for *GALR1* and *SALL3*, significant inverse correlations were found between mRNA expression and DNA methylation in this cohort. Furthermore, for the TCGA cohort, we found that *GALR1* and *SALL3* were the best prognostic markers for patients with HNSCC. Our findings provide evidence that *GALR1* and *SALL3* methylation might represent a good biomarker to predict HNSCC recurrence. This could facilitate HNSCC screening and the development of surveillance programs.

*GALR1* is one of three G-protein coupled receptors (GPCRs) for galanin, a neuropeptide encoded by the *GALR1* gene that is widely expressed in several peripheral tissues including the gastrointestinal tract, skeletal muscle, heart, kidney, uterus, ovary, and testis, in addition to the central nervous system \[[@B17-cancers-11-00401]\]. GALR1-transfected HNSCC cells demonstrated decreased cell proliferation and colony formation after galanin stimulation \[[@B18-cancers-11-00401]\]. Thus, *GALR1* might represent a tumor suppressor in HNSCC. Recently, it was reported that aberrant *GALR1* promoter methylation is significantly associated with shortened survival in salivary duct carcinoma patients \[[@B19-cancers-11-00401]\]. The presence of *GALR1* methylation in vaginal swabs also indicates the presence of endometrial malignancy with a sensitivity of 92.7% and a specificity of 78.9% \[[@B20-cancers-11-00401]\]. Therefore, *GALR1* DNA methylation is one common molecular alteration in human cancers ([Table 4](#cancers-11-00401-t004){ref-type="table"}).

The product of *NFATC1* is a component of the nuclear factor of activated T cells DNA-binding transcription complex. Hypomethylation of the promoter region of *NFATC1* was identified in chronic lymphocytic leukemia patients and found to correlate with disease stage \[[@B21-cancers-11-00401]\]. Strong *NFATC1* expression was also found to be significantly associated with worse patient outcomes in urothelial carcinoma \[[@B22-cancers-11-00401]\]. Furthermore, *NFATC1* overexpression in high-grade serous ovarian carcinoma is an independent prognostic factor of poor overall survival and early relapse \[[@B23-cancers-11-00401]\]. *NFATC1* might thus play a causative role in oncogenesis ([Table 4](#cancers-11-00401-t004){ref-type="table"}). In HNSCC, *NFATC1* comprises a region that still needs to be explored. Our results indicated that *NFATC1* hypermethylation occurs with extremely low frequency and is not associated with outcome.

Vertebrate spalt proteins are classified into four groups, encoded by four genes in humans, namely *SALL1--4* \[[@B24-cancers-11-00401]\]. Four genes have also been identified in mice, namely Sall1--4, whereas three have been found in chickens, three in zebrafish, and five in xenopus \[[@B24-cancers-11-00401]\]. *SALL3* is an epigenetic hotspot for aberrant DNA methylation and is associated with abnormal placental development in mice \[[@B25-cancers-11-00401]\]. Several clinical studies have been carried out to investigate the association between *SALL3* and carcinogenesis. Shikauchi et al. reported that *SALL3* can be silenced by DNA methylation and that the encoded protein interacts with DNA methyltransferases 3 alpha (DNMT3A) in hepatocellular carcinoma \[[@B26-cancers-11-00401]\]. Aberrant hypermethylation of *SALL3* is also positively associated with HPV infection in cervical cancer \[[@B27-cancers-11-00401]\]. Furthermore, recurrent bladder cancer patients were found to display higher proportions of *SALL3* DNA methylation compared to that in non-recurrent bladder cancer patients \[[@B28-cancers-11-00401]\]. Accordingly, methylation profiling of urine sediments, to detect the top four frequently methylated genes, namely *SALL3*, *CFTR*, *ABCC6*, and *HPP1*, together can detect bladder cancer with 82.6% sensitivity and 100% specificity \[[@B29-cancers-11-00401]\]. The *SALL3* gene might thus play a role in the tumorigenesis and could serve as an important biomarker for human cancers ([Table 4](#cancers-11-00401-t004){ref-type="table"}).

In this study, we present a more comprehensive epigenetic analysis of chromosome 18q23 including its methylation patterns in HNSCC and normal mucosal tissues. Our study is the first to investigate the pattern of DNA methylation at chromosome 18q23, as well as its relationship with poor survival and early relapse. Regarding cancer risk, we also showed that there might also be a role for DNA methylation at this important cancer susceptibility locus.

4. Methods {#sec4-cancers-11-00401}
==========

4.1. Tumor Samples of Original Cohort {#sec4dot1-cancers-11-00401}
-------------------------------------

In total, 243 primary HNSCC samples were obtained from patients during surgery at the Department of Otolaryngology, Hamamatsu University School of Medicine. The samples were obtained soon after diagnosis and were thus from untreated tumors. Pertinent information including age, sex, smoking status, alcohol consumption, primary tumor site, tumor size, lymph node status, and clinical stage was obtained from the patients' medical records. The male:female ratio in the patient cohort was 208:35. The mean age was 65.1 years (range, 32--92 years). Primary tumors were in the hypopharynx (*n* = 58), larynx (*n* = 47), oropharynx (*n* = 66), or oral cavity (*n* = 72). All patients provided written informed consent, and the study protocol was approved by the Institutional Review Board of the Hamamatsu University School of Medicine (date of board approval: 2 October 2015, ethic code: 25-149).

4.2. Target Gene Selection {#sec4dot2-cancers-11-00401}
--------------------------

Examination of the number and size of CpG islands and the density of CpG sites in upstream and downstream flanking sequences of the transcription start sites of ADNP homeobox 2 (*ADNP2*), myelin basic protein (*MBP*), small integral membrane protein 21 (*SMIM21*), and zinc finger protein 407 (*ZNF407*) was eliminated from the study targets since they did not contain CpG islands within the target regions. We therefore selected 12 genes located on 18q23 (*ATP9B*, *CTDP1*, *GALR1*, *HSBP1L1, KCNG2*, *NFATC1*, *PARD6G*, *PQLC1*, *RBFA*, *SALL3*, *TXNL4A* and *ZNF516*), which had CpG islands in their transcription start sites. A CpG island is defined as a DNA segment fulfilling the following three conditions: (i) length of the segment is at least 200 bp, (ii) G and C contents are ≥50%, and (iii) the observed CpG to expected CpG ratio is ≥0.6 \[[@B30-cancers-11-00401]\].

4.3. Q-MSP Analysis {#sec4dot3-cancers-11-00401}
-------------------

Extraction and bisulfite conversion of genomic DNA from 243 primary HNSCC and 36 noncancerous mucosal samples were performed using the MethylEasy Xceed Rapid DNA Bisulfite Modification Kit (TaKaRa, Tokyo, Japan), as per the manufacturer's instructions \[[@B31-cancers-11-00401],[@B32-cancers-11-00401]\]. The bisulfite-modified DNA was used as a template for fluorescence-based real-time PCR \[[@B2-cancers-11-00401]\]. The methylation levels of the CpG islands in the promoters of the 12 genes located on 18q23 were determined via Q-MSP with the TaKaRa Thermal Cycler Dice Real Time System TP800 (TaKaRa). A list of the primer sequences for Q-MSP analysis is shown in [Table S2](#app1-cancers-11-00401){ref-type="app"}. Exon structures and CpG sites within the expanded views of the promoter region relative to the transcription start site are presented in [Figure S6](#app1-cancers-11-00401){ref-type="app"}. A standard curve was constructed by plotting known concentrations of serially-diluted EpiScope Methylated HeLa gDNA (TaKaRa). NMVs were determined as follows: NMV = (target gene-S/target gene-FM)/(ACTB-S/ACTB-FM), where target gene-S and target gene-FM represent target gene methylation levels in the tumor sample and universal methylated DNA control, respectively, and ACTB-S and ACTB-FM represent *ACTB* (which encodes β-actin) methylation levels in the sample and control, respectively. For amplification reactions, 2 μL (0.01 μg/μL) of bisulfite-treated genomic DNA, 12.5 μL of SYBR^®^ Premix DimerEraser TM Perfect Real Time (TaKaRa), and 0.5 μL (10 μM) of each primer were added to a final volume of 25 μL. The PCR conditions were as follows: one denaturing cycle at 95 °C for 10 s, followed by 40 cycles of denaturing at 95 °C for 5 s and annealing/extension at 58 °C for 30 s (two-step reaction). Dissociation curves were carried out at the end of each PCR by following a 3-step procedure. Analysis was performed using the software (version 1.03A) for the Thermal Cycler Dice Real Time System TP800 (TaKaRa), according to the manufacturer's directions \[[@B33-cancers-11-00401],[@B34-cancers-11-00401]\].

4.4. Analysis of HPV Status {#sec4dot4-cancers-11-00401}
---------------------------

To assess HPV status, samples were also subjected to PCR using specific primers for HPV types 16, 18, 31, 33, 35, 52 and 58. The PCR HPV Typing Set (TaKaRa) method was performed according to the manufacturer's protocol. The PCR products were separated using 9% polyacrylamide gel electrophoresis followed by ethidium bromide staining.

4.5. Collection of Publicly Available Data from TCGA {#sec4dot5-cancers-11-00401}
----------------------------------------------------

Aberrant DNA methylation data available in TCGA (January 2019) were collected via the MethHC database (<http://methhc.mbc.nctu.edu.tw/php/index.php>) using the Infinium HumanMethylation450 platform (Illumina, Inc., San Diego, CA, USA) and were expressed as β values. The β value is a number between 0 (not methylated) and 1 (completely methylated) that represents the ratio of methylated allele intensity to overall intensity \[[@B35-cancers-11-00401]\]. A conservative cut-off comprising β-values \> the median values of normal TCGA samples was used to call samples as methylated. Cutoff levels were determined to be 0.029 for *ATP9B*, 0.143 for *GALR1*, 0.083 for *HSBP1L1*, 0.873 for *KCNG2*, 0.044 for *NFATC1*, 0.067 for *PARD6G* and 0.099 for *SALL3*.

4.6. Literature Review {#sec4dot6-cancers-11-00401}
----------------------

A search of the PubMed database using the following terms was performed to identify studies reporting genes in which the detection of methylation or expression was significantly associated with their use as a biomarker for prognosis and diagnosis: "target gene name" AND "cancer" AND "survival" OR "diagnosis" ([Table 4](#cancers-11-00401-t004){ref-type="table"}).

4.7. Data Analysis and Statistics {#sec4dot7-cancers-11-00401}
---------------------------------

The Q-MSP results and patient characteristics (age of onset, sex, smoking status, alcohol consumption, HPV status, tumor size, lymph node status, clinical stage and recurrence events) were compared using a Student's *t*-test. Receiver-operator characteristic (ROC) curve analysis was conducted using the NMVs for 36 HNSCC and 36 adjacent normal mucosal samples with the Stata/SE 13.0 system (Stata Corporation, College Station, TX, USA). Prediction accuracy was assessed using the area under the ROC curve. Cut-off values showing the greatest accuracy were determined based on sensitivity/specificity, as indicated in [Table S3](#app1-cancers-11-00401){ref-type="app"}. The cut-off values were used to determine the methylation frequencies of the target genes. The overall methylation rates in the individual samples were determined by calculating the MI. The MI was defined as the ratio of the number of methylated genes to the number of tested genes in each sample \[[@B34-cancers-11-00401],[@B36-cancers-11-00401]\].

DFS was measured from the date of the initial treatment to the date of diagnosis of first recurrence, either locoregional or systemic. Survival curves were plotted using the Kaplan--Meier method and significance was assessed by the log-rank test. The prognostic value of methylation status was assessed by performing multivariate Cox proportional hazards analysis adjusting for age (≥70 versus \<70 years), HPV status, smoking status, alcohol intake, and tumor stage (I, II and III versus IV). A *p*-value less than 0.05 was considered statistically significant. All statistical analyses were performed using StatMate IV software (IV version, ATMS Co. Ltd., Tokyo, Japan).

5. Conclusions {#sec5-cancers-11-00401}
==============

The current study provides evidence that detecting aberrant *GALR1* and *SALL3* methylation can serve as a means to identify critical events in HNSCC progression. As such, the promoter methylation status of 18q23 genes might be an important marker to explain distinct tumor patterns and behaviors with HNSCC. Our findings support the use of methylation markers to select patients for adjuvant therapy after initial surgical treatment; however, our preliminary findings need to be validated in larger and more homogeneous HNSCC patient cohorts.
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![Methylation of genes located on 18q23 in head and neck squamous cell carcinoma (HNSCC) samples. (**a**) flow chart of the selection of candidate genes; (**b**) bar graph showing the methylation frequencies of the seven genes in the original cohort (red bars) and TCGA cohort (blue bars). (**c**) bar graph comparing the number of HNSCC cases to the number of methylated genes in the original cohort (red bars) and TCGA cohort (blue bars).](cancers-11-00401-g001){#cancers-11-00401-f001}

###### 

Kaplan--Meier survival curves for the 243 patients with HNSCC according to the methylation status of the seven target genes. Disease-free survival based on (**a**) ATP9B, (**b**) GALR1, (**c**) HSBP1L1, (**d**) KCNG2, (**e**) NFATC1, (**f**) PARD6G, and (**g**) SALL3 methylation; methylated (red lines) and unmethylated (blue lines) cases are shown; (**h**) joint analysis of GALR1 and SALL3 genes. blue line: patients with both unmethylated genes; green line: patients with either methylated gene; red line: patients with both methylated genes. A probability of \<0.05 (\* *p* \< 0.05) was considered a statistically significant difference.
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###### 

Distribution of methylation status by selected epidemiologic and clinical characteristics in the original cohort.

  Gene                 ATP9B                GALR1         HSBP1L1       KCNG2         NFATC1       PARD6G        SALL3                                                                                                      
  -------------------- -------------------- ------------- ------------- ------------- ------------ ------------- ------------- ------------ ----------- ------------- ------------ ------------- ------------- ------------ ----
  Characteristics      Methylation status   Yes           No            Yes           No           Yes           No            Yes          No          Yes           No           Yes           No            Yes          No
  Overall (%)          90 (37.0%)           153 (63.0%)   120 (49.4%)   123 (50.6%)   74 (30.5%)   169 (69.5%)   144 (59.3%)   99 (40.7%)   22 (9.1%)   221 (90.9%)   98 (40.3%)   145 (59.7%)   161 (66.3%)   82 (33.7%)   
  Age                  \<70                 64            95            81            78           49            110           99           60          17            142          65            94            103          56
  \>70                 26                   58            39            45            25           59            45            39           5           79            33           51            58            26           
  *p* ^†^                                   0.165                       0.59                       0.658                       1                        0.25                       0.891                       0.569        
  Gender               Female               13            22            13            22           10            25            20           15          3             32           12            23            23           12
  Male                 77                   131           107           101           64           144           124           84           19          189           86           122           138           70           
  *p* ^†^                                   1                           0.144                      0.846                       1                        1                          0.463                       1            
  Smoking status       Smoker               72            115           95            92           56            131           117          70          20            167          73            114           125          62
  Non-smoker           18                   38            25            31            18           38            27            29           2           54            25           31            36            20           
  *p* ^†^                                   0.433                       0.449                      1                           0.064                    0.118                      1                           1            
  Alcohol exposure     Drinker              68            116           94            90           54            130           112          72          19            165          76            108           126          58
  Non-drinker          22                   37            26            33            20           39            32            27           3           56            22           37            35            24           
  *p* ^†^                                   1                           0.372                      1                           1                        0.301                      0.649                       1            
  HPV status           Positive             17            29            28            18           9             37            28           18          5             41           23            23            34           12
  Negative             73                   124           92            105           65           132           116           81           17          180           75           122           127           70           
  *p* ^†^                                   1                           0.102                      0.078                       0.869                    1                          1                           0.299        
  Tumor size           T1--2                47            75            56            66           37            85            68           54          11            111          44            78            86           36
  T3--4                43                   78            64            57            37           84            76            45           11          110           54           67            75            46           
  *p* ^†^                                   0.691                       0.306                      1                           0.3                      1                          0.192                       0.176        
  Lympho-node status   N0                   33            65            46            52           27            71            58           40          6             92           34            64            63           35
  N+                   57                   88            74            71            47           98            86            59           16          129           64           81            98            47           
  *p* ^†^                                   0.417                       0.601                      0.478                       1                        0.255                      0.146                       1            
  Stage                I--III               37            67            47            57           31            73            61           43          5             99           37            67            67           37
  IV                   53                   86            73            66            43           96            83            56           17          122           61           78            94            45           
  *p* ^†^                                   0.69                        0.3                        0.889                       1                        0.069                      0.234                       1            
  Recurrence events    Positive             31            54            52            33           32            53            50           35          10            75           35            50            64           21
  Negative             59                   99            68            90            42           116           94            64           12          146           63           95            97            61           
  *p* ^†^                                   1                           0.007 \*                   1                           1                        1                          1                           0.033 \*     

^†^ Chi-squared test, \* *p* \< 0.05.

cancers-11-00401-t002_Table 2

###### 

Distribution of methylation status by selected epidemiologic and clinical characteristics in the TCGA cohort.

  Gene                 ATP9B                GALR1         HSBP1L1       KCNG2        NFATC1        PARD6G        SALL3                                                                                                          
  -------------------- -------------------- ------------- ------------- ------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------ ----
  Characteristics      Methylation status   Yes           No            Yes          No            Yes           No            Yes           No            Yes           No            Yes           No            Yes          No
  Overall(%)           174 (33.7%)          342 (66.3%)   495 (95.9%)   21 (4.1%))   201 (39.0%)   315 (61.0%)   354 (68.6%)   162 (31.4%)   361 (70.0%)   155 (30.0%)   149 (28.9%)   367 (71.1%)   443 (85.9%)   73 (14.1%)   
  Age                  \<70                 142           258           383          17            154           246           269           131           286           114           114           286           337          63
  \>70                 31                   84            111           4            47            68            84            31            74            41            34            81            105           10           
  *p* ^†^                                   0.094                       1                          1                           0.256                       1                           1                           0.068        
  Gender               Female               48            93            138          3             74            67            86            55            92            49            46            95            125          16
  Male                 126                  249           357           18           127           248           268           107           269           106           103           272           318           57           
  *p* ^†^                                   1                           0.216                      \<0.001 \*                  1                           1                           1                           0.321        
  Smoking status       Smoker               132           250           367          15            135           247           269           113           271           111           118           264           326          56
  Non-smoker           39                   83            116           6            63            59            77            45            85            37            31            91            107           15           
  *p* ^†^                                   0.661                       1                          0.002 \*                    1                           1                           0.257                       0.554        
  Alcohol exposure     Drinker              107           237           329          15            140           204           233           111           238           106           106           238           295          49
  Non-drinker          61                   100           155           6            55            106           114           47            113           48            41            120           138           23           
  *p* ^†^                                   1                           0.816                      0.171                       0.537                       0.837                       0.248                       1            
  Tumor size           T1--2                58            150           200          8             80            128           143           65            142           66            68            140           181          27
  T3--4                116                  192           295           13           121           187           211           97            219           89            81            227           262           46           
  *p* ^†^                                   0.023 \*                    1                          0.855                       0.3                         1                           1                           0.607        
  Lympho-node status   N0                   67            155           218          4             95            127           145           77            150           72            66            156           195          27
  N+                   106                  180           269           17           101           185           203           83            207           79            83            203           240           46           
  *p* ^†^                                   0.11                        0.024 \*                   1                           1                           1                           1                           0.251        
  Stage                I--III               56            153           203          6             90            119           149           60            145           64            67            142           182          27
  IV                   118                  189           292           15           111           196           205           102           216           91            82            225           261           46           
  *p* ^†^                                   0.006 \*                    0.364                      1                           0.289                       1                           1                           0.524        

^†^ Chi-squared test, \* *p* \< 0.05.

cancers-11-00401-t003_Table 3

###### 

Methylation status of individual genes and associations with disease-free survival using Cox proportional hazards model in 243 patients.

  Gene      Methylation Status   Overall (%)   Recurrence Events   Adjusted RR (95% CI) ^†^   
  --------- -------------------- ------------- ------------------- -------------------------- --
  ATP9B     Yes                  90 (37.0%)    31                  59                         
  No        153 (63.0%)          54            99                  0.831 (0.531--1.301)       
  GALR1     Yes                  120 (49.4%)   52                  68                         
  No        123 (50.6%)          33            90                  1.600 (1.027--2.493) \*    
  HSBP1L1   Yes                  74 (30.5%)    32                  42                         
  No        169 (69.5%)          53            116                 1.016 (0.644--1.603)       
  KCNG2     Yes                  144 (59.3%)   50                  94                         
  No        99 (40.7%)           35            64                  1.199 (0.761--1.890)       
  NFATC1    Yes                  22 (9.1%)     10                  12                         
  No        221 (90.9%)          75            146                 1.455 (0.731--2.897)       
  PARD6G    Yes                  98 (40.3%)    35                  63                         
  No        145 (59.7%)          50            95                  1.116 (0.719--1.731)       
  SALL3     Yes                  161 (66.3%)   64                  97                         
  No        82 (33.7%)           21            61                  1.911 (1.155--3.162) \*    
  MI        5--6                 34 (14.0%)    17                  17                         
  0--4      209 (86.0%)          68            141                 1.609 (0.932--2.778)       

^†^ Adjusted for age, gender, smoking status, alcohol exposure and stage. \* *p* \< 0.05; CI: confidence interval. RR: recurrence ratio.

cancers-11-00401-t004_Table 4

###### 

Published studies of 18q23 genes and biomarkers for patients.

  Genes Studied            Study (Ref.)                                    Year   Country          Cases   Disease                        Significant Association with Survival and Diagnosis
  ------------------------ ----------------------------------------------- ------ ---------------- ------- ------------------------------ ------------------------------------------------------------------------------------------------------
  GALR1 hypermethylation   Kanazawa T et al. \[[@B19-cancers-11-00401]\]   2018   Japan            34      salivary duct carcinoma        Worse survival (*p* = 0.026)
  GALR1 hypermethylation   Doufekas K et al. \[[@B20-cancers-11-00401]\]   2013   United Kingdom   64      endometrial cancer             Vaginal swabs for detection of endometrial cancer; a sensitivity of 92.7% and a specificity of 78.9%
  NFATC1 hypomethylation   Wolf C et al. \[[@B21-cancers-11-00401]\]       2018   Germany          130     Chronic lymphocytic leukemia   Disease progression stages (*p* \< 0.05)
  NFATC1 overexpression    Kawahara T et al. \[[@B22-cancers-11-00401]\]   2017   Japan            99      urothelial carcinoma           Lower progression-free survival (*p* = 0.032)
  NFATC1 overexpression    Li L et al. \[[@B23-cancers-11-00401]\]         2016   China            93      ovarian cancer                 Worse overall survival (*p* \< 0.01)
  SALL3 hypermethylation   Heijden AG et al. \[[@B28-cancers-11-00401]\]   2018   Spain            458     bladder cancer                 Higher recurrence rate (*p* \< 0.001)
  SALL3 hypermethylation   Wei X et al. \[[@B27-cancers-11-00401]\]        2015   China            23      cervical cancer                HPV infection positive relationship (*p* = 0.010, *r* = 0.408)
  SALL3 hypermethylation   Yu J et al. \[[@B29-cancers-11-00401]\]         2007   China            132     bladder cancer                 Urine sediments for detection of bladder cancer; a sensitivity of 58.3% and a specificity of 100%
